Related Experiment Video
Updated: Jun 30, 2025
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
8.1K
Prognostic evaluation of lymph-vascular space invasion in patients with endometrioid and non-endometrioid endometrial
Jie Feng1, Yue Zhang1, Changzhen Huang1
1Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China; Division of Gynecology Oncology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Summary
Lymph-vascular space invasion (LVSI) negatively impacts disease-free survival in endometrioid endometrial cancer (EC) but not overall survival. LVSI does not affect survival outcomes in non-endometrioid EC patients.
Area of Science:
- Gynecologic Oncology
- Pathology
- Cancer Research
Background:
- Lymph-vascular space invasion (LVSI) is a controversial prognostic marker in endometrial cancer (EC).
- Understanding LVSI's impact across different EC subtypes is crucial for accurate prognostication.
Purpose of the Study:
- To investigate the prognostic significance of LVSI in endometrioid and non-endometrioid EC.
- To evaluate the association of LVSI with disease-free survival (DFS) and overall survival (OS) in Chinese EC patients.
Main Methods:
- Retrospective analysis of 3715 EC patients from 2010-2019 across seven Chinese hospitals.
- Stratification by histopathologic type and LVSI status, followed by propensity score matching (PSM).
- Kaplan-Meier analysis and Cox proportional hazards regression for survival outcomes.
Main Results:
- LVSI was detected in 9.31% of EC patients.
- In endometrioid EC, LVSI correlated with shorter DFS (P=0.005) but not OS (P=0.656) post-matching.
- No significant association between LVSI and DFS or OS was found in non-endometrioid EC patients.
Conclusions:
- LVSI is an adverse prognostic factor for endometrioid EC, impacting disease-free survival.
- LVSI does not appear to be a significant prognostic factor for non-endometrioid EC.
- Adjuvant therapy decisions for non-endometrioid EC should carefully consider LVSI status.
